文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

HACOR评分对急诊急性呼吸衰竭患者HFNO失败的前瞻性验证

Prospective validation of HACOR score for HFNO failure in emergency department patients with acute respiratory failure.
PubMed 文献 · Am J Emerg Med · 2026-08-22
一句话结论急诊ARF患者HFNO启动后60分钟HACOR评分可良好区分48小时内HFNO失败,>5阈值用于排除失败,≥8阈值仅为探索性。

单中心前瞻性研究纳入332例急诊急性呼吸衰竭启动HFNO的成人患者,在T0和T60计算HACOR评分。主要终点为48小时内插管或全因死亡(HFNO失败),发生率为35.2%。T60 HACOR的AUC为0.890,显著优于T0的0.701,校准良好,在10-60%阈值概率区间有正净获益。T60 HACOR≥8的敏感度86.3%、特异度76.7%;>5的敏感度94.9%、特异度42.3%、NPV 93.8%。

要点

  • 急诊ARF患者启动HFNO后60分钟应计算HACOR评分,T60 AUC 0.890(95%CI 0.853-0.927),显著优于T0的0.701(ΔAUC +0.189,p<0.001)。
  • T60 HACOR>5用于排除HFNO失败:敏感度94.9%、特异度42.3%、NPV 93.8%,原文称其仍为排除失败的参考阈值。
  • T60 HACOR≥8为探索性阈值:敏感度86.3%、特异度76.7%(bootstrap校正后85.5%和76.3%),需前瞻性验证。
  • 校准良好:cross-validated slope 0.98,calibration-in-the-large -0.001,无校准不良证据。
  • 决策曲线分析显示在10-60%阈值概率区间有正净获益。

适用人群与场景

  • 单中心三级学术急诊科,因急性呼吸衰竭启动HFNO的成人患者,且在HFNO启动时(T0)和60分钟(T60)有动脉血气数据。

诊断标准与关键阈值

  • HACOR评分在HFNO启动时(T0)和60分钟(T60)计算。
  • T60 HACOR>5:敏感度94.9%、特异度42.3%、NPV 93.8%,原文称仍为排除失败的参考阈值。
  • T60 HACOR≥8:敏感度86.3%、特异度76.7%(bootstrap校正后85.5%和76.3%),原文称该阈值由本研究导出,为探索性,需前瞻性验证。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:单中心前瞻性队列验证研究;样本量332例;中位年龄71岁,男性47.0%。
  • 主要终点HFNO失败(48小时内插管或全因死亡)发生117例(35.2%),其中115例(98.3%)插管。
  • T60 HACOR区分度AUC 0.890(95%CI 0.853-0.927),优于T0的0.701(95%CI 0.645-0.757),ΔAUC +0.189,p<0.001。
  • 校准:cross-validated slope 0.98,calibration-in-the-large -0.001,无校准不良证据。
  • 决策曲线分析:在10-60%阈值概率区间有正净获益。
  • T60 HACOR≥8在75.5%的bootstrap重采样中被选中;亚组AUC范围0.856-0.912。

证据类型、等级与局限

  • 证据类型:单中心前瞻性队列验证研究。
  • 局限:单中心、探索性阈值需前瞻性验证;原文未提及证据等级或推荐强度。

对床旁实践的改变

  • 对急诊ARF启动HFNO的成人患者,应在60分钟时计算HACOR评分以评估失败风险,而非仅依赖启动时评分。
  • T60 HACOR>5可用于排除HFNO失败(NPV 93.8%),但特异度低(42.3%),阳性者不一定需要立即插管。
  • T60 HACOR≥8为探索性阈值,原文明确需前瞻性验证,不应作为常规决策阈值。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: High-flow nasal oxygen (HFNO) failure occurs in 30-42% of emergency department (ED) patients with acute respiratory failure (ARF). The HACOR score was derived in intensive care patients on mask-based noninvasive ventilation; its performance during HFNO in unselected ED patients has not been prospectively validated.

METHODS: Adults started on HFNO for ARF with arterial blood gas data at HFNO initiation (T0) and at 60 min (T60) were prospectively enrolled at a single tertiary academic ED. The primary outcome was HFNO failure (intubation or death from any cause within 48 h). We assessed discrimination (AUC, DeLong method), calibration (cross-validated slope) and clinical utility (decision curve analysis); the Youden-optimal T60 threshold was derived, bootstrap-corrected for optimism, and compared with the original cutoff (HACOR >5).

RESULTS: Of 332 patients (median age 71 years; 47.0% male), 117 (35.2%) failed HFNO, of whom 115 (98.3%) were intubated. T60 HACOR outperformed T0 (AUC 0.890 [95% CI 0.853-0.927] vs. 0.701 [0.645-0.757]; ΔAUC +0.189; p < 0.001), showed no evidence of miscalibration (slope 0.98; calibration-in-the-large -0.001), and showed positive net benefit at threshold probabilities of 10-60%. HACOR ≥8 at T60 gave sensitivity 86.3% and specificity 76.7% (bootstrap-corrected 85.5% and 76.3%; selected in 75.5% of resamples); HACOR >5 gave sensitivity 94.9%, specificity 42.3% and NPV 93.8%. Subgroup AUCs ranged 0.856-0.912.

CONCLUSION: The 60-min HACOR score discriminates HFNO failure well, with no evidence of miscalibration, in an unselected ED cohort, substantially outperforming the admission score. The >5 threshold remains the reference for ruling out failure; the ≥8 threshold derived here is exploratory and requires prospective validation.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Unal E, Altunbas E, Karavin EO, et al. Prospective validation of HACOR score for HFNO failure in emergency department patients with acute respiratory failure. Am J Emerg Med. 2026. PMID: 42659770. doi:10.1016/j.ajem.2026.08.038

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。